In an effort to bring our clients access to innovative companies and solutions that help achieve the best patient outcomes, we will be featuring some of our Accenture Intelligent Patient Service Exchange (IPEX) partners to show how they play a role in the evolving life sciences ecosystem.
In our inaugural post, we’ve invited Andrew Goldberg, co-founder and COO of HealthVerity, to share how the company’s products and services, in conjunction with Accenture’s data analysis and analytics, artificial intelligence and machine learning capabilities, offer an enhanced view of the patient journey—a key piece of the puzzle that has often been missing for life sciences companies working to improve patient outcomes.
HealthVerity, based in Center City Philadelphia, is transforming the way data-led organizations make critical decisions. Its technology platform serves as the foundation for the rapid creation, exchange, and management of healthcare and consumer data in a fully-interoperable, privacy-protecting manner. Advantaged by highly sophisticated identity resolution and matching capabilities, HealthVerity is on a mission to increase transparency, forge interoperability and activate deeper insights.
In the past, healthcare data has been incredibly fragmented and disconnected, with patient and provider information distributed across numerous parties. HealthVerity helps pull all this data together to provide visibility into the entire patient journey—from how patients are progressing and what comorbidities are present to how their behavior is changing and how adherent they are in taking their medicines—all anonymously and with HIPAA compliance.
Without this visibility, it’s very difficult for healthcare providers to understand what medications or treatments, combined with various patient management approaches, are going to change the outcome for a patient. And since outcomes are the new healthcare currency for healthcare providers, payers and patients, these kinds of insights are now more critical than ever before.
HealthVerity has also sought to fill a number of gaps in the existing system, including the lack of interoperability between data sets, such as between clinical and consumer lifestyle data. In some cases, this type of data has not been accessible at all and simply gaining access to it has been a complex challenge in itself.
Making the Most of Volumes of Data
Another challenge has been the trend of ever-increasing amounts of available data. For example, some patients with diabetes now have access to devices that continuously monitor their blood glucose levels. Where once they would have manually taken between four and ten measurements a day, they can now generate a reading every six seconds – that’s over 14,000 measurements in one 24-hour period – thanks to a continuous monitoring device.
With all these new data points available, HealthVerity wanted to find a way to aggregate the data. The HealthVerity Census solution does just that, enabling customers to associate a unique but persistent ‘token’ with individuals, so that a person’s anonymous data can be exchanged and followed across systems, as permitted by HIPAA. This enables the streamlining and consolidating of duplicate datasets, even when data contains anomalies such as typographic errors or nicknames, all while maintaining patient confidentiality and anonymity.
For Accenture’s clients, access to HealthVerity Census means being able to conduct analytics and glean insights in ways they have only previously dreamed of, following the patient journey across pharmacy data, loyalty cards, copayments and credit cards. And where there are gaps in data, clients can reach out to the HealthVerity Marketplace to leverage anonymized data from additional sources.
As an example, you could look at the journey of patients with multiple sclerosis (MS). The treatments for MS are complicated and need to be carefully managed on many different fronts. Using HealthVerity Census, you could identify a group of patients within a particular program and determine whether or not they are filling their prescriptions and following their treatment plan. If they are not, you can look at other data, including lifestyle and consumer data such as household size and credit scores, to discover possible reasons why they are not adherent to their treatment plan. Once you understand the issues, whether it’s inconvenience, expense or something else, you could determine a course of action—a patient education program or another intervention that could boost compliance and improve patient outcomes.
Being an IPEX partner allows us to work with Accenture clients in a powerful way, investing in and analyzing the data needed to solve a particular challenge (we call this the minimum viable data or MVD). What we have already been able to achieve together shows the tremendous value in belonging to an ecosystem and the benefits of encouraging members with complimentary skills to collaborate and innovate in ways where we have only just scratched the surface.